In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on PAVmed (PAVM – Research Report). The company’s shares closed yesterday at $0.24.
Vendetti covers the Healthcare sector, focusing on stocks such as Icecure Medical, Biolase, and Aethlon Medical. According to TipRanks, Vendetti has an average return of -3.2% and a 32.06% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PAVmed with a $7.50 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $1.38 and a one-year low of $0.22. Currently, PAVmed has an average volume of 520K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.
Read More on PAVM:
- PAVmed reports Q2 EPS (9c), two estimates (19c)
- PAVmed Provides Business Update and Second Quarter Financial Results
- Lucid Diagnostics Provides Business Update and Second Quarter Financial Results
- PAVM Earnings this Week: How Will it Perform?
- PAVmed receives 180-day extension to regain Nasdaq compliance
